Immunological network signatures of cancer progression and survival
- 8.6k Downloads
The immune contribution to cancer progression is complex and difficult to characterize. For example in tumors, immune gene expression is detected from the combination of normal, tumor and immune cells in the tumor microenvironment. Profiling the immune component of tumors may facilitate the characterization of the poorly understood roles immunity plays in cancer progression. However, the current approaches to analyze the immune component of a tumor rely on incomplete identification of immune factors.
To facilitate a more comprehensive approach, we created a ranked immunological relevance score for all human genes, developed using a novel strategy that combines text mining and information theory. We used this score to assign an immunological grade to gene expression profiles, and thereby quantify the immunological component of tumors. This immunological relevance score was benchmarked against existing manually curated immune resources as well as high-throughput studies. To further characterize immunological relevance for genes, the relevance score was charted against both the human interactome and cancer information, forming an expanded interactome landscape of tumor immunity. We applied this approach to expression profiles in melanomas, thus identifying and grading their immunological components, followed by identification of their associated protein interactions.
The power of this strategy was demonstrated by the observation of early activation of the adaptive immune response and the diversity of the immune component during melanoma progression. Furthermore, the genome-wide immunological relevance score classified melanoma patient groups, whose immunological grade correlated with clinical features, such as immune phenotypes and survival.
The assignment of a ranked immunological relevance score to all human genes extends the content of existing immune gene resources and enriches our understanding of immune involvement in complex biological networks. The application of this approach to tumor immunity represents an automated systems strategy that quantifies the immunological component in complex disease. In so doing, it stratifies patients according to their immune profiles, which may lead to effective computational prognostic and clinical guides.
KeywordsMelanoma Gene Ontology Text Mining Immune Gene Immune Component
Although a link between the immunity and cancer was observed almost 150 years ago , the exact nature of the relationship has been developed and debated through several stages of complexity. In recent years, it has been established that the immune system plays crucial roles in tumor development , and indeed on patient survival for various cancers [3, 4, 5, 6, 7]. Due to a lack of comprehensive analytical approaches, molecular characterization of the roles of the tumor immune component has been somewhat difficult to elucidate on a genome-wide scale.
Current strategies to identify the immune component of tumors tend to employ incomplete manual efforts that do not grade the immune genes. Indeed, even the very definition of an immune gene is unclear, as several interconnected subsystems comprise the totality of immunity. In addition, an analysis of the molecular interactions linked to tumor immunity is usually limited to a pathway-centric paradigm, which is often hindered by the complexity in which immune pathways are entangled in signaling crosstalk . These challenges are further complicated during cancer progression by the migration of immune cells into unique microenvironments, and by the altered expression of immune genes intrinsic to the tumor. Consequently, as in a tumor gene expression profile, it is not trivial to grade the immune component or identify its related molecular networks.
Multidisciplinary and integrated strategies that handle these and other complex challenges of tumor immunity are increasingly sought after [9, 10, 11, 12, 13, 14, 15, 16]. With recent advances in genomics, and increased amounts of latent detailed knowledge in the medical literature, computational approaches can now be developed to study the importance of immune genes and their networks of interactions linked to cancer progression.
Consequently, we have devised a strategy that assigns a ranked immunological relevance score to all human genes for the purpose of profiling the immune component of tumor gene expression. Coupling text mining to information theory, this approach charts immunological relevance onto the human interactome. To apply this strategy in a cancer specific manner, we analyzed melanomas. We first identified immunological signatures that were differentially regulated in the progression from primary stages of skin cancer through to metastases . Survival data from a set of advanced stage melanoma patients were also analyzed, to assess the link between immunological relevance of genes in expression profiles and clinical outcome [5, 18].
Our computational approach to assign immunological relevance to genes was benchmarked against manual efforts that identify immune genes, and the strategy was shown to substantiate the performance of existing immunological grading systems. Furthermore, it identified the ranked immunological components of the expression profile of a tumor with its associated networks of interactions. This informative grading of the magnitude of the immune component from patient gene expression profiles may serve as a computational diagnostic and prognostic guide to assess the aggressiveness of a given tumor.
An information theoretical approach to assign immunological relevance to genes
A comprehensive list of 1921 immunology terms was compiled by manual selection of the most relevant terms from the standard biomedical vocabularies of Medical Subject Headings (MeSH) in Medline and the Gene Ontology (GO) controlled vocabulary (see Methods: "Defining the dictionary of terms for immune and neoplasm relevance"). This broad set of terms was collectively considered to be the immunological symbols of communication stored in the over 20 million articles of the biomedical literature (Additional file 1). Using established text mining procedures  (see Methods: "Extraction of human genes, immune and neoplasm terms from Medline"), we used these terms and their relationships to gene citations in Medline by capitalizing on the universal feature of coded information, present in all forms of communication. By this, it is implied that immune relevant genes have a level of immune information content quantified using this combined set of immune terms in Medline, which is greater than that of genes that play a lesser role in the immune system. Information theory calculations were used to measure the size of the immunological message stored for each human gene with respect to these terms. The probabilities in the information theory calculations were defined through the frequency by which a given gene is cited with a given immune term relative to the number of times the immune term is cited in Medline among all human genes with that term. This measure of immune information content for a gene may be biased by the higher frequency of certain genes being associated overall with the sources of the immune terms, i.e. the popularity of a gene among all terms in the biomedical vocabularies. This bias was corrected for using a method in information theory known as the Kullback-Leibler (KL) divergence (see Methods: "An immunological and cancer relevance score for all human genes using information theory and text mining"). The KL score for all human genes was defined as the "immunological relevance" for a gene and termed as such throughout this study (Additional file 2). A similar strategy was also applied to a manual selection of 562 cancer disease terms to determine a genome-wide cancer relevance score for every human gene.
Benchmarking of the immunological relevance score and the extension of immune gene resources
The interactome landscape of immunological and cancer relevance
Immunological comparisons of normal tissues and robustness of tissue specific immune interactions
Immunological networks signatures and clinical outcome from expression profiles in melanoma patients
Top ranked immunological transitions of melanoma progression
Gene comparison conditions
Highest graded immune genes
Significance to Melanoma progression
Upregulated (> 2fc) in both primary and metastatic melanoma compared to normal melanocyte (Immunological relevance score for each gene (KL) > 11 bits).
CD4, IL10, CD8A, CD40, IL15, IL7, IL18, TNFSF13B, PTPRC, IL13RA2, IL1A, PECAM1, C5AR1, CD86, ISG20, IL18R1, CD14, ITGB2, ADORA3, FCGR3A, CCL2, IL8, CCR5, FCGR3B
Signatures of T-cell infiltration, T-cell activation and the inflammatory response. Inclusive of the Th1 inhibiting cytokines
Downregulated (> 2fc) in both primary and metastatic melanoma compared to normal melanocyte (Immunological relevance score for each gene (KL) > 0.5 bits).
MME, IL24, DPP4, CYGB, MSC, SLC7A8
Regulation of extracellular matrix (ECM) remodeling, through proteolytic enzymes, and amino acid transporters
Upregulated (> 2fc) in primary melanoma compared to normal melanocyte. Not subject to >2fc in metastasis (Immunological relevance score for each gene (KL) > 2 bits).
IL5, TNF, IL1RN, DARC, HLA-DRB4, CFP, PTPN6, CD1B, ELA2, IL17B, ATP8A2, SLPI, CD27, STAT4, CDA, IL26, DEFB4, NFKBIA, HRH1, XCL1, DEFB1, PDPN, CTSG, SDC1, GATA3, MSMB, CD24, POU1F1, PRDM1, EBF1
Cytokine activity that is pro-survival and towards ECM remodeling. Increased transcriptional activity related to T-cell activation in the primary tumor. Increased presence of MHC class II markers.
Downregulated (> 2fc) in primary melanoma compared to normal melanocyte. Not subject to >2fc in metastasis (Immunological relevance score for each gene (KL) > 1 bit).
BAX, TNFRSF10B, SV2A
Down-regulation is indicative of p53 dysfunction and transduction of apoptosis signals. Overall leading to pro-survival in the primary tumor compared to normal cells
Upregulated (> 2fc) in metastatic melanoma compared to normal melanocyte. Not subject to >2fc in primary. (Immunological relevance score for each gene (KL) > 1 bit).
CCRL2, HLA-DRB1, MDK, C4A, CD55, CD80, FCGR1A, KLRC4, ICAM1, SPI1, HCST, PPBP, FCGR2C, GPR160, CXCL16, FOS, SERPINA1
Mediators of inflammation, angiogenesis, cell growth, and cell migration. Also present are signals of humoral immunity in the form of T-cell activation and B-cell development genes
Downregulated (> 2fc) in metastatic melanoma compared to normal melanocyte. Not subject to >2fc in primary. (Immunological relevance score for each gene (KL) > 1 bit).
KIT, IRF4, MLANA, MMP1
Down regulation of cell adhesion, differentiation factors and regulators of the innate and adaptive immune systems. Possibly promoting the metastatic phenotype
Upregulated (> 2fc) in metastatic melanoma compared to primary (Immunological relevance score for each gene (KL) < 1 bit).
MAGEA3, CSAG2, MAGEA2, GAGE1, MAGEA12, GAGE3, FKBP10
Eliciting immune T cell activation in metastatic tumors, as a consequence of being expressed particularly in the metastatic stages, while having very restricted expression in normal cells
Downregulated (> 2fc) in metastatic melanoma compared to primary (Immunological relevance score for each gene (KL) > 1 bit).
S100A9, S100A8, SLPI, DEFB4, DEFB1, MSMB, CD24, DEFB103A, COL17A1
Altered matrix remodeling and migratory behavior. Dynamic changes in the (ECM) in the metastatic tumors. Inclusive in this is the down regulation of important chemoattractants of innate immune cells
A composite gene expression and immunological relevance score was used to grade each patient expression profile and find clinical trends to immunological gene signatures (see Methods: "Microarray gene expression analysis and a composite expression and immunological relevance score"). Although the Riker et al. study was not accompanied by clinical outcome data, there was a trend in two patients with giant primary melanomas (Breslow thickness of 90 mm) and downregulation of highly relevant immunological genes (p-val, 0.02) compared to 12 other patients with primary melanomas. Using this composite grade, we examined the immunological differences in the outcome, as well as in other clinical features of 57 patients that had reached metastatic melanoma at stage IV  and 38 patients at stage III (Bogunovic et at, 2009). Notably, there was a significant association (p-val, 0) with the "high-immune" group of patients as annotated by Jonsson et al (as identified by one term, chosen a-priori). Similarly, the strategy detected downregulated highly relevant immunological genes in the patient group that fell into the "proliferative" group of patients (p-val, 0). An upregulated immunological trend was detected in patients that had favorable survival (p-val, 0.1) and was more significant (p-val, 0.02) in those patients categorized with "brisk" immune phenotype (infiltration of CD3 positive lymphocytes). The patient group with NRAS mutations (Q61L) had a correlation with downregulated immunological signatures (p-val, 0.007), hence classifying a group of patients with immune signaling interactions acting downstream of this oncogenic mutation. Patients with hypermethylation of the p16INK4A promoter had trends towards upregulation of genes with high immunological relevance (p-val, 0.05). Overall, the trends with immunological grading of these expression profiles indicated that the assignment of an immunological relevance to genes could classify patient groups with varied immunological signatures. The same analysis was applied to 38 patients from (Bogunovic et al, 2009), and it revealed a significant correlation of upregulated immunological signatures in patients with prolonged survival (p-val, 0.0086) and a significant correlation of downregulated gene with patients that died (p-val, 0.0074). This was also the case in Jonsson et al, where each patient had a unique profile of clinical annotations and immunological gene expression levels (Additional file 7). Interestingly, the authors reported positive correlation with tumor infiltrating leukocytes (TILs) in those patients with favorable survival. A summary of these trends with patient clinical annotations and the immunological profiles for each patient is listed in Additional file 7.
The overlap between cancer and immunity has become increasingly well established in recent years. Epidemiologically, 15-20% of cancer deaths are associated to inflammatory conditions . Furthermore, inflammation is a predisposition to cancer, and polymorphisms in cytokine genes are associated to cancer severity [27, 28]. Although there is compelling evidence that supports this overlap, an understanding of the molecular mechanisms of what constitutes tumor-immune relationships is far from comprehensive [2, 29]. This problem is complicated further by the uniqueness of the microenvironment of each tumor, and the complex interplay between cancer cell immune factors and immune cells infiltrating the tumor.
Gene expression profiling has the potential to provide an improved understanding of these complex relationships and address these challenges. Current approaches to assess the immune component of expression profiles are dependent upon the application of limited pre-defined sets of immune genes or terms. Prerequisite to the success of manual approaches is the challenge of defining the complete set of immune genes. We have demonstrated that this challenge has not been met. The crux in overcoming this challenge lies in what may be considered to be an immune relevant gene. One option to find immune genes with a role in cancer development is the use of expertly annotated databases [20, 30, 31, 32]. Our approach improves on the limitations of manual approaches by applying a novel automated procedure that quantifies the immunological relevance for all human genes in bits of information. This score can be directly applied to and provide a more informative and quantitative assessment of the tumor immune component from the gene expression profile. The novel use of information bits to quantify the immunological component may be even further generalized, and applied to any phenotype or any other entity having been assigned symbols of written communication.
Having access to a ranked immunological relevance score for all genes provided an opportunity for analysis of the resulting interactome landscape for tumor immunity. This provided interesting insights into the relationships with levels of immune and cancer information of a gene in the interactome, in light of the new paradigm of network biology [23, 33]. These observations in particular add to the debate of the importance of central positions held by cancer  and immune  genes in the cellular interactome network. Although there is on average higher connectivity for immune and cancer genes in those studies, we illustrated variation about the average, with certain peak genes raising the average connectivity in the interactome landscape.
Tissue specific expression analysis of the immunological relevance score demonstrated that there is a detectable difference among different tissues in the expression of immune genes. Tissue specific network analysis demonstrated that immune genes have distinguishably robust connections within a cells interactome. These observations may be explained by the diverse properties of various tissues to interplay with the immune system in maintaining tissue homeostasis. The strategy of applying a computationally derived immunological score to capture the heterogeneity of the immunological component of normal tissues adds reason to its application as an immunological meta-analysis to cancer transcriptomes. Indeed, quantifying the immunological component of expression studies linked to clinical annotations can lead to informative insights into the immune profiles of patient groups. The necessity and timeliness of applying such a comprehensive computational strategy to tumor expression profiles is highlighted by the increasing reports of immune cell infiltrates in tumor microenvironments as predictors of prognosis and survival in various cancers [4, 5, 7, 36, 37, 38, 39, 40, 41].
A proposition for an immunological grading of a tumor based on immune infiltrates has recently been made , which would require the expertise of highly trained pathologists. Recent studies in malignant melanoma advocate stratification based on molecular signatures from expression profiling [5, 18]. The computational approach described here serves in the automatic identification of ranked immunological signatures and their network of interactions, which leads to a strategy of grading the immunological component of the gene expression of a tumor.
Melanoma was chosen to be the cancer type to demonstrate this strategy, because of the prominent immunological properties of normal skin [43, 44] and the strong tendency of melanoma to metastasize . Among the genes harboring some of the highest immunological relevance, and with expression differences in both primary and metastatic profiles compared to normal skin, were the CD4 and CD8 genes. This indicates that our strategy pinpoints possible recruitment of the adaptive immune response at early points in the progression of melanoma in these tumors, which is interesting in the context of increasing evidence that adaptive immunity influences the behavior of human tumors . With respect to melanoma, this further coincides with recent evidence in mice that the metastatic transition is an early event, and that proliferation of disseminating cells is mediated by the function of CD8+ T-cells . Concerning clinical analysis of metastatic melanoma patients, this approach classified the patient group that had immune signatures of upregulated high immunologically relevant genes, and the proliferative-tumor group with down downregulation of high immunologically relevant genes. It was apparent from the clinical analysis that patients had unique combinations of clinical annotations with both up and downregulated genes with high immunological scores. The distinctive immunological profiles for each patient may reflect the uniqueness of the immune component of each microenvironment and the contradictory role immune genes play in regulating cancer development .
This strategy does not grade the directionality of these paradoxical roles in the tumor immune response. Rather, it identifies and grades the magnitude of the immune component of the expression profiles. We propose, however, that improving this strategy to do so will precipitate the characterization of detailed mechanisms underlying tumor-immune surveillance, tolerance and escape and facilitate identification of powerful prognostic factors.
We have assigned a ranked immunological relevance score to all human genes applying a novel computational approach that utilizes information theory applied to the medical literature. This score was used to chart immunological relevance against the landscape of protein interaction networks. We propose that this approach can be applied to elucidate the phenotypical component of any complex disease. In this study we focus on tumor immunity and melanoma to demonstrate the ability of this strategy to identify and grade the magnitude of the immune component of patient expression profiles. The capability to analyze tumor transcriptional profiles on a genome-wide scale offers a means to investigate the immunological mechanisms of the complex tumor immune relationships. In so doing, such an approach can classify melanoma patient groups into varied immune profiles that correlate with survival and other clinical phenotypes.
Defining the dictionary of terms for immune and neoplasm relevance
By doing manual searches in the Gene Ontology (GO)  and the Medical Subject Headings (MeSH) (http://www.nlm.nih.gov/mesh/) resources and documenting those terms deemed relevant for the context, we compiled a list of 1921 immune and 562 neoplasm context terms. This resulted in a comprehensive term list from structured vocabularies that define the contexts in our analysis. The manual searches were implemented using domain knowledge of immunity and cancer. Strict scrutiny of relevance to the context was applied before acceptance of a term into the context term list. The manual searches in MesH and GO produced a candidate list of terms. Each candidate term was read and then categorized as being relevant or not relevant for immunity or cancer based on the expert knowledge of an immunologist or cancer researcher, respectively. As the purpose of this study was to quantify the size of the immune component of tumor samples, a broad scope of immune terms was accepted, each term has an association of an immune function, process, cellular anatomy or immune condition according to the scrutiny of the immunologist. The complete list of chosen immune and neoplasm terms is presented in Additional file 1.
Extraction of human genes, immune and neoplasm terms from Medline
One of the important elements in the approach is to identify literature co-citations of human genes and their associated GO and MeSH terms by using an established method in text mining . Here is a brief summary of this method with more detail in the referenced article. All official symbols, names and alias symbols for human genes compiled from the Human Genome Organization (HUGO) (http://www.genenames.org/), OMIM (http://www.ncbi.nlm.nih.gov/omim/), and EntrezGene (http://www.ncbi.nlm.nih.gov/gene), were automatically extracted from all Medline article titles and abstracts. The genes are indexed to PubMed IDs after a natural language processing (NLP) step of the Medline abstracts that involves procedures in part of speech tagging (POS) and noun chunking, the purpose of which is to remove false positives of biological term mentions. Some other steps in obtaining the gene citation data of higher quality is to remove abbreviation type false positives, which occur frequently because gene symbols often coincide with other abbreviations having no connection or relevancy with the gene symbol. Such data quality steps yield a greater number unambiguous gene symbol citations in text with an improved precision. In a similar manner to the extractions of gene from Medline text GO terms are extracted using NLP techniques of POS and the GO terms mapped to their corresponding identifiers and indexed against noun chunks in Medline sentences. MeSH terms are indexed to Medline abstracts by using the National Library of Medicine's (NLM) annotations of MeSH terms to articles.
An immunological and cancer relevance score for all human genes using information theory and text mining
The principle of Shannon's entropy was first tested as a sensible measure of information content applied to gene associations derived from text mining. This was further refined using the Kullback-Leibler (KL) score, thus correcting for bias introduced by the popularity of the gene to be co-cited in all of Medline which we found to inherent in the Shannon entropy calculations.
As this relative entropy score (KL) corrects for the bias q(x) for each gene, it was used as to calculate the "immunological and cancer relevance" score throughout this study.
Collating manually curated immune relevant gene sets
The immunology gene sets were compiled from the following manually curated sources: (1) Immport (https://www.immport.org), (2) Immunome , (3) Iris , (4) Mapk-Nfkb (ref), (5) Septic Shock (http://www.septicshock.org) and (6) InnateDB . The HUGO (http://www.genenames.org/) symbol for genes provides a unique identifier for human genes and is ideal for the integration of text mining derived knowledge. It was used in this study to integrate and determine the overlapping descriptive statistics for each of the six databases and visualized in Venn diagrams in the VennMaster software  to approximate their intersections by incorporating the gene set size information. Similarly genes from two efforts to catalogue the inflammatory response [21, 22] were integrated using their HUGO gene symbols and compared to the unified immune gene set from the above six different sources mentioned above.
Constructing a validated human interactome & network analysis
We constructed a human gene network by integrating binary human interactions from IntAct , BioGRID  and HPRD . Each of these datasets of binary interacting protein pairs was downloaded from their source and the unique ids of the interactors were cross-referenced to their NCBI gene IDs and official Gene Symbols. This resulted in a unified set of binary NCBI gene ID interactor pairs, with their corresponding official gene symbols. The interaction data was limited to these sources as they consist of validated protein-protein interactions with experimental evidence curated from critical reading of the scientific literature by expert biologists.
This integrated data set is represented as an undirected, unweighted network, where G = (V,E) comprising of a set of nodes V and edges E. Each node represents a human gene and each edge represents a pair of genes (u,v) as a representation of a binary interaction in the human interactome. If there exists a physical binary interaction between u and v, in at least one of the protein products of each gene, an edge is connected. The tissue specific interactomes were derived from the entries in the three protein interaction databases mentioned above and the tissue expression annotations from in a recent study integrating tissue specific interactions from 79 human tissues .
Network centrality analysis was carried out on the networks by means of calculating five measures of centrality for each gene in the interactome (Connectivity, betweeness, eccentricity, closeness and eigenvector). A descriptions of equations implemented for these measures and full details of their context to protein networks in cancer are summarized here 
Microarray gene expression analysis and a composite expression and immunological relevance score
The patient scores where compared to the clinical annotations to find correlations between the weighted immunological score (Wp) and the clinical phenotypes. Monte Carlo simulations with 10,000 draws were used to create a null distribution for each comparison. For numerical phenotypes Pearson's correlation were used.
The research leading to these results has received funding from the European Commision (FP6-2005-NEST-PATH, No. 043241 - ComplexDis and FP7-2008, No 223367-MultiMod).
- 1.Virchow RL: Die Krankhaften Geschwülste Dreissig Vorlesungen gehalten während des Wintersemesters 1862-63 Vierte Vorlesung. 1863, Berlin, 1: 65.Google Scholar
- 4.Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, et al: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004, 351: 2159-2169. 10.1056/NEJMoa041869.CrossRefPubMedGoogle Scholar
- 5.Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, Darvishian F, Berman R, Shapiro R, Pavlick AC, et al: Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA. 2009, 106: 20429-20434. 10.1073/pnas.0905139106.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Disis ML: Immune Regulation of Cancer. Journal of Clinical Oncology. 2010Google Scholar
- 9.Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH, et al: Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2010, 138 (4): 1429-1440. 10.1053/j.gastro.2009.10.057.CrossRefPubMedGoogle Scholar
- 14.Mlecnik B, Sanchez-Cabo F, Charoentong P, Bindea G, Pagès F, Berger A, Galon J, Trajanoski Z: Data integration and exploration for the identification of molecular mechanisms in tumor-immune cells interaction. BMC Genomics. 2010, 11 (Suppl 1): S7-10.1186/1471-2164-11-S1-S7.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS, et al: The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics. 2008, 1: 13-10.1186/1755-8794-1-13.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Jonsson GB, Busch C, Knappskog S, Geisler J, Miletic H, Ringner M, Lillehaug JR, Borg A, Lonning PE: Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome. Clin Cancer Res. 2010Google Scholar
- 38.Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006, 313: 1960-1964. 10.1126/science.1129139.CrossRefPubMedGoogle Scholar
- 39.Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C, Corbu A, Perra MT, Sirigu P: The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer. 2005, 104: 1246-1254. 10.1002/cncr.21283.CrossRefPubMedGoogle Scholar
- 40.van Houdt IS, Sluijter BJR, Moesbergen LM, Vos WM, de Gruijl TD, Molenkamp BG, van den Eertwegh AJM, Hooijberg E, van Leeuwen PAM, Meijer CJLM, et al: Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer. 2008, 123: 609-615. 10.1002/ijc.23543.CrossRefPubMedGoogle Scholar
- 41.Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005, 102: 18538-18543. 10.1073/pnas.0509182102.CrossRefPubMedPubMedCentralGoogle Scholar
- 46.Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, Tan TG, Zheng L, Ong LC, Jin Y, et al: Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest. 2010, 120: 2030-2039. 10.1172/JCI42002.CrossRefPubMedPubMedCentralGoogle Scholar
- 49.Shannon CE: A Mathematical Theory of Communication. The Bell System Technical Journal. 1948, 379-423. 623-656Google Scholar
- 52.Peri S, Navarro JD, Kristiansen TZ, Amanchy R, Surendranath V, Muthusamy B, Gandhi TKB, Chandrika KN, Deshpande N, Suresh S, et al: Human protein reference database as a discovery resource for proteomics. Nucleic Acids Research. 2004, 32: D497-501. 10.1093/nar/gkh070.CrossRefPubMedPubMedCentralGoogle Scholar
- 54.Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004, 3: Article3Google Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1755-8794/4/28/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.